588 related articles for article (PubMed ID: 30146351)
21. Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer.
Min L; Zhang C; Qu L; Huang J; Jiang L; Liu J; Pinello L; Yuan GC; Shou C
Oncotarget; 2017 Mar; 8(13):21938-21953. PubMed ID: 28423538
[TBL] [Abstract][Full Text] [Related]
22. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.
Pan Y; Yuan Y; Liu G; Wei Y
PLoS One; 2017; 12(2):e0172324. PubMed ID: 28235003
[TBL] [Abstract][Full Text] [Related]
23. p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
Coradini D; Biganzoli E; Ardoino I; Ambrogi F; Boracchi P; Demicheli R; Daidone MG; Moliterni A
Breast; 2015 Jun; 24(3):294-7. PubMed ID: 25698149
[TBL] [Abstract][Full Text] [Related]
24. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
25. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
[TBL] [Abstract][Full Text] [Related]
26. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
Narrandes S; Huang S; Murphy L; Xu W
BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
[TBL] [Abstract][Full Text] [Related]
27. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
28. Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.
Ou-Yang F; Pan MR; Chang SJ; Wu CC; Fang SY; Li CL; Hou MF; Luo CW
Life Sci; 2019 Dec; 238():116963. PubMed ID: 31639396
[TBL] [Abstract][Full Text] [Related]
29. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
[TBL] [Abstract][Full Text] [Related]
30. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
31. Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India.
; Parshad R; Kazi M; Seenu V; Mathur S; Dattagupta S; Haresh KP
Indian J Cancer; 2017; 54(4):658-663. PubMed ID: 30082553
[TBL] [Abstract][Full Text] [Related]
32. Recent Progress in Triple Negative Breast Cancer Research.
Mouh FZ; Mzibri ME; Slaoui M; Amrani M
Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
[TBL] [Abstract][Full Text] [Related]
33. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
34. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Garrido-Castro AC; Lin NU; Polyak K
Cancer Discov; 2019 Feb; 9(2):176-198. PubMed ID: 30679171
[TBL] [Abstract][Full Text] [Related]
35. MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer.
Mathe A; Scott RJ; Avery-Kiejda KA
Int J Mol Sci; 2015 Nov; 16(12):28347-76. PubMed ID: 26633365
[TBL] [Abstract][Full Text] [Related]
36. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
37. Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?
Moran MS
Am Soc Clin Oncol Educ Book; 2014; ():e32-6. PubMed ID: 24857120
[TBL] [Abstract][Full Text] [Related]
38. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes.
DiNome ML; Orozco JIJ; Matsuba C; Manughian-Peter AO; Ensenyat-Mendez M; Chang SC; Jalas JR; Salomon MP; Marzese DM
Ann Surg Oncol; 2019 Oct; 26(10):3344-3353. PubMed ID: 31342401
[TBL] [Abstract][Full Text] [Related]
40. Long noncoding RNAs in triple-negative breast cancer: A new frontier in the regulation of tumorigenesis.
Thakur KK; Kumar A; Banik K; Verma E; Khatoon E; Harsha C; Sethi G; Gupta SC; Kunnumakkara AB
J Cell Physiol; 2021 Dec; 236(12):7938-7965. PubMed ID: 34105151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]